网红黑料

University of Florida scientists announced today (3/18) they have received a $3.4 million grant from AstraZeneca Pharmaceuticals LP to help speed the flow of cardiovascular research findings to health-care professionals in the community.

The funds will allow the UF-based international Vascular Biology Working Group to expand its ongoing educational programs, providing opportunities for health practitioners to review and exchange scientific data in an effort to transfer new treatments to patients with heart disease as quickly as possible.

鈥淭his educational grant is an important contribution to our efforts to provide programs to fill critical educational needs of practicing physicians. In today鈥檚 information age, new scientific and clinical discoveries are emerging at a pace that is so rapid the practicing physician just simply cannot keep up,鈥� said Carl J. Pepine, M.D., the working group鈥檚 program chairman and chief of the division of cardiovascular medicine at UF鈥檚 College of Medicine. 鈥淭he Vascular Biology Working Group provides an opportunity for physicians to teach other physicians about the innovations that are reshaping therapeutic approaches to many common diseases, particularly in cardiovascular medicine.鈥�

As part of its ongoing commitment to the working group, AstraZeneca will provide program support focused on heart failure management.

鈥淲ith the increasing prevalence of cardiovascular disease worldwide, providing an educational forum where scientific and clinical information can be exchanged has become vital in helping physicians gain an understanding of therapeutic advancements in cardiovascular medicine,鈥� said Adele Gulfo, vice president of AstraZeneca鈥檚 U.S. cardiovascular therapeutic area. AstraZeneca, based in Wilmington, Del., is an international health-care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of health-care services.

To date, the working group has sponsored more than 600 conferences worldwide involving more than 8,000 participants in the field of cardiovascular disease. It was formed in 1994 to unify the broad spectrum of cardiovascular science that is driving the advances related to prevention and management of coronary artery disease.